FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.

Date publication

janvier 2018

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Pr BRUNOTTE François , Pr FUMOLEAU Pierre , Pr COCHET Alexandre

Tous les auteurs :
Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30011328

Résumé

Evaluate response and predict prognosis of patients with newly diagnosed metastatic breast cancer treated with first line systemic therapy using European Organization for Research and Treatment of Cancer (EORTC) criteria and PET Response Criteria in solid Tumours (PERCIST).

Mots clés

Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Breast Neoplasms, diagnostic imaging, Female, Fluorodeoxyglucose F18, Follow-Up Studies, Humans, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Positron Emission Tomography Computed Tomography, methods, Proportional Hazards Models, Retrospective Studies

Référence

PLoS ONE. 2018 ;13(7):e0199529